Literature DB >> 19942691

Changes in antibiotic susceptibility and ribotypes in Clostridium difficile isolates from southern Scotland, 1979-2004.

Surabhi K Taori1, Val Hall2, Ian R Poxton1.   

Abstract

An increase in the incidence of clinical cases of Clostridium difficile infection has been reported in recent years, but few studies have examined changes in molecular epidemiology and antibiotic resistance over a long period of time. A collection of 179 isolates of C. difficile obtained from symptomatic adult patients in southern Scotland between 1979 and 2004 was used to determine changes in the prevalence of epidemiological types and antibiotic susceptibilities to common antibiotics. PCR ribotyping and MIC determination were performed on all isolates. A total of 56 different ribotypes were identified, among which ribotype 002 was the commonest type overall (14 .0%), followed by ribotypes 014 (7.3 %), 012 (5 .0%), 015 (5.0 %), 020 (5 .0%) and 001 (4.5 %). Ribotype 078 was also identified. The 10 commonest ribotypes comprised 55 % of the total isolates. Ribotype 001 increased in prevalence from 1.5 to 12.2 % over the study years, whereas the prevalence of ribotype 012 decreased from 8.7 to 2 .0%. Resistance to clindamycin, erythromycin and ceftriaxone was found in 95.5, 14.0 and 13.4 % of isolates, respectively. Resistance to vancomycin or metronidazole was not detected. Thirty-two (17.9 %) and 14 (7.8 %) isolates were resistant to two and three or more antibiotics, respectively. Ribotype 001 displayed maximum resistance, with 50 % of isolates resistant to erythromycin, moxifloxacin and ceftriaxone, and 100 % resistant to clindamycin. Over the 26 years of the study, antibiotic resistance and ribotype prevalence have changed, and antibiotic pressures may have been the major driver of this change.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19942691     DOI: 10.1099/jmm.0.014829-0

Source DB:  PubMed          Journal:  J Med Microbiol        ISSN: 0022-2615            Impact factor:   2.472


  6 in total

1.  Sensitivity to antibiotics of Clostridium difficile toxigenic nosocomial strains.

Authors:  Vladimir Beran; Dittmar Chmelar; Jana Vobejdova; Adela Konigova; Jakub Nemec; Josef Tvrdik
Journal:  Folia Microbiol (Praha)       Date:  2013-10-11       Impact factor: 2.099

2.  Molecular and microbiological characterization of Clostridium difficile isolates from single, relapse, and reinfection cases.

Authors:  Kentaro Oka; Takako Osaki; Tomoko Hanawa; Satoshi Kurata; Mitsuhiro Okazaki; Taki Manzoku; Motomichi Takahashi; Mamoru Tanaka; Haruhiko Taguchi; Takashi Watanabe; Takashi Inamatsu; Shigeru Kamiya
Journal:  J Clin Microbiol       Date:  2012-01-11       Impact factor: 5.948

3.  Activity of a novel cyclic lipopeptide, CB-183,315, against resistant Clostridium difficile and other Gram-positive aerobic and anaerobic intestinal pathogens.

Authors:  D R Snydman; N V Jacobus; L A McDermott
Journal:  Antimicrob Agents Chemother       Date:  2012-03-05       Impact factor: 5.191

4.  U.S.-Based National Sentinel Surveillance Study for the Epidemiology of Clostridium difficile-Associated Diarrheal Isolates and Their Susceptibility to Fidaxomicin.

Authors:  D R Snydman; L A McDermott; N V Jacobus; C Thorpe; S Stone; S G Jenkins; E J C Goldstein; R Patel; B A Forbes; S Mirrett; S Johnson; D N Gerding
Journal:  Antimicrob Agents Chemother       Date:  2015-08-03       Impact factor: 5.191

5.  Characterization of temperate phages infecting Clostridium difficile isolates of human and animal origins.

Authors:  Ognjen Sekulovic; Julian R Garneau; Audrey Néron; Louis-Charles Fortier
Journal:  Appl Environ Microbiol       Date:  2014-02-14       Impact factor: 4.792

6.  Antimicrobial susceptibility of clostridium difficile clinical isolates in iran.

Authors:  Mehdi Goudarzi; Hossein Goudarzi; Masoud Alebouyeh; Masoumeh Azimi Rad; Farahnaz Sadat Shayegan Mehr; Mohammad Reza Zali; Mohammad Mehdi Aslani
Journal:  Iran Red Crescent Med J       Date:  2013-08-05       Impact factor: 0.611

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.